Boston Scientific Co. (NYSE:BSX) Director Charles J. Dockendorff Sells 3,946 Shares

Boston Scientific Co. (NYSE:BSX - Get Free Report) Director Charles J. Dockendorff sold 3,946 shares of the company's stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $72.70, for a total transaction of $286,874.20. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Boston Scientific Stock Down 1.0 %

Shares of BSX traded down $0.71 during midday trading on Wednesday, reaching $72.72. The stock had a trading volume of 5,036,563 shares, compared to its average volume of 6,595,854. Boston Scientific Co. has a 1-year low of $48.35 and a 1-year high of $74.39. The company's fifty day simple moving average is $68.68 and its two-hundred day simple moving average is $61.74. The company has a market cap of $106.69 billion, a price-to-earnings ratio of 61.11, a PEG ratio of 2.51 and a beta of 0.77. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.66 and a quick ratio of 1.14.

Institutional Trading of Boston Scientific

A number of large investors have recently made changes to their positions in the company. Bruce G. Allen Investments LLC purchased a new position in shares of Boston Scientific during the fourth quarter worth about $28,000. RiverPark Advisors LLC purchased a new position in shares of Boston Scientific in the 1st quarter valued at approximately $30,000. Northwest Investment Counselors LLC acquired a new position in shares of Boston Scientific in the first quarter valued at approximately $31,000. Sachetta LLC purchased a new stake in shares of Boston Scientific during the fourth quarter worth approximately $32,000. Finally, Frazier Financial Advisors LLC acquired a new stake in shares of Boston Scientific during the fourth quarter worth $32,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BSX has been the subject of a number of recent research reports. Raymond James increased their price objective on shares of Boston Scientific from $73.00 to $85.00 and gave the company a "strong-buy" rating in a report on Thursday, April 25th. StockNews.com downgraded shares of Boston Scientific from a "buy" rating to a "hold" rating in a report on Saturday, March 16th. Royal Bank of Canada increased their price objective on shares of Boston Scientific from $78.00 to $82.00 and gave the company an "outperform" rating in a report on Thursday, April 25th. Evercore ISI increased their price objective on shares of Boston Scientific from $72.00 to $78.00 and gave the company an "outperform" rating in a report on Thursday, April 25th. Finally, Wells Fargo & Company increased their price target on shares of Boston Scientific from $72.00 to $82.00 and gave the company an "overweight" rating in a research note on Thursday, April 25th. Three analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $75.09.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.